313 related articles for article (PubMed ID: 9826434)
1. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.
Cheung PP; Yu L; Zhang H; Colman RW
Arch Biochem Biophys; 1998 Dec; 360(1):99-104. PubMed ID: 9826434
[TBL] [Abstract][Full Text] [Related]
2. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
3. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
4. Platelet cyclic adenosine monophosphate phosphodiesterases: targets for regulating platelet-related thrombosis.
Colman RW
Semin Thromb Hemost; 2004 Aug; 30(4):451-60. PubMed ID: 15354266
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
6. Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.
Tang KM; Jang EK; Haslam RJ
Biochem J; 1997 Apr; 323 ( Pt 1)(Pt 1):217-24. PubMed ID: 9173884
[TBL] [Abstract][Full Text] [Related]
7. Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis.
Cheung PP; Xu H; McLaughlin MM; Ghazaleh FA; Livi GP; Colman RW
Blood; 1996 Aug; 88(4):1321-9. PubMed ID: 8695850
[TBL] [Abstract][Full Text] [Related]
8. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
Manns JM; Brenna KJ; Colman RW; Sheth SB
Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
[TBL] [Abstract][Full Text] [Related]
10. Conserved amino acids in metal-binding motifs of PDE3A are involved in substrate and inhibitor binding.
Zhang W; Colman RW
Blood; 2000 Jun; 95(11):3380-6. PubMed ID: 10828019
[TBL] [Abstract][Full Text] [Related]
11. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the presence of essential histidine and cysteine residues in platelet cGMP-inhibited phosphodiesterase.
Ghazaleh FA; Omburo GA; Colman RW
Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):495-501. PubMed ID: 8713077
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Liu H; Maurice DH
Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
[TBL] [Abstract][Full Text] [Related]
14. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the relationship between protein-protein interaction and catalytic activity of a heme-regulated phosphodiesterase from Escherichia coli (Ec DOS) by protein microarray.
Sasakura Y; Kanda K; Yoshimura-Suzuki T; Matsui T; Fukuzono S; Shimizu T
Biochemistry; 2005 Jul; 44(28):9598-605. PubMed ID: 16008345
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain.
Jin SL; Swinnen JV; Conti M
J Biol Chem; 1992 Sep; 267(26):18929-39. PubMed ID: 1326538
[TBL] [Abstract][Full Text] [Related]
17. A new nonhydrolyzable reactive cAMP analog, (Sp)-adenosine-3',5'-cyclic-S-(4-bromo-2,3-dioxobutyl)monophosphorothioate irreversibly inactivates human platelet cGMP-inhibited cAMP phosphodiesterase.
Hung SH; Madhusoodanan KS; Beres JA; Boyd RL; Baldwin JL; Zhang W; Colman RW; Colman RF
Bioorg Chem; 2002 Feb; 30(1):16-31. PubMed ID: 11955000
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
20. The Rv0805 gene from Mycobacterium tuberculosis encodes a 3',5'-cyclic nucleotide phosphodiesterase: biochemical and mutational analysis.
Shenoy AR; Sreenath N; Podobnik M; Kovacevic M; Visweswariah SS
Biochemistry; 2005 Dec; 44(48):15695-704. PubMed ID: 16313172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
